IDH1 and astrocytoma (excluding glioblastoma): The article confirms the hypothesis in astrocytoma/glioblastoma cell lines, in which exogenous expression of the mutated IDH1 results in a three- to 10-fold increase in temozolomide resistance after long-term passage [18].